Retrospective case series of aripiprazole augmentation in pervasive developmental disorders

Psychiatry Investigation

Volumn 7, Issue 3, 2010, Pages 220-223

  Kim, Yeni ^a,b   Cho, Soo Churl ^a   Shin, Min Sup ^a   Kim, Jae Won ^a   Lee, Seung Hee ^a,c   Kim, Boong Nyun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Junior Mind Clinic Didim Secho   (South Korea)

Author keywords

Aripiprazole; Augmentation; Autism; Pervasive developmental disorder

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; METHYLPHENIDATE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADOLESCENT; AGGRESSION; AKATHISIA; ARTICLE; AUTISM; AUTOMUTILATION; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MALE; MASTURBATION; OBSESSION; PSYCHOSIS; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TIC; TREATMENT RESPONSE; VOMITING;

EID: 77957738828     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2010.7.3.220     Document Type: Article

References (10)

1. National Institutes of Health. 'Autism fact sheet' NINDS. Bethesda, MD: National Institutes of Health; 2006.
2. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-336.
3. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multi-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008;165:1432-1441.
4. Stigler KA, Posy DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-463. (Pubitemid 39473132)
5. Andersen SE, Johansson M, Manniche C. The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric inpatients. Basic Clin Pharmacol Toxicol 2008;103:75-81.
6. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009;19:265-274.
7. Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009;23: 511-521.
8. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005;20:603-610.
9. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16: 549-560. (Pubitemid 44737210)
10. Woods SW. Chlorpromazine equvalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.